Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and almost 38,900 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim RSS Channel

Filters
List of articles in category Boehringer Ingelheim
Title Published Date
Boehringer Ingelheim gains approval of extended 4.5 hour time-window for Actilyse® 04 December 2011
Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab 01 December 2011
Boehringer Ingelheim implements additional guidance supporting appropriate use of Pradaxa® (dabigatran etexilate) in Europe 01 November 2011
Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors 12 October 2011
European Respiratory Society (ERS) Awards Annual COPD Research Prize 28 September 2011
Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe 14 September 2011
Boehringer Ingelheim wins Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing 09 September 2011
€1 Million Awarded to Winning Projects 30 August 2011
Trajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe 26 August 2011
Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology 18 August 2011
Positive first half-year 2011 for Boehringer Ingelheim 12 August 2011
PRADAXA® first drug in 50 years to gain approval for stroke prevention in atrial fibrillation 05 August 2011
Stroke prevention: "It is time to act" 26 July 2011
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled 12 April 2011
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim 15 March 2011
Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement 15 February 2011
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance 16 January 2011
LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients 09 December 2010
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day 16 November 2010
Collaboration of Boehringer Ingelheim and VTU Technology 11 November 2010